Conceptus Named Fourth Fastest Growing Medical Equipment Company in Deloitte's Technology Fast 500 Program.

Developers of Essure([R]) System for Permanent Birth Control Achieve Top 50 Overall Ranking and Top Three Ranking Among Silicon Valley Companies

MOUNTAIN VIEW, Calif. -- Conceptus Inc. (Nasdaq:CPTS), developer of the Essure procedure, the first and only non-incisional permanent birth control method available, has been named to Deloitte's prestigious Technology Fast 500 Program. This is a ranking of the fastest growing technology, media, telecommunications and life sciences companies by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2001-2005.

The company was ranked fourth in the Medical Equipment category and ranked 49th overall on the Technology Fast 500 list. Additionally, the company achieved a top three ranking in the Silicon Valley's Fastest Growing Scientific & Medical Equipment and Biotechnology Companies in Deloitte's Technology Fast 50 Program.

Conceptus' CEO Mark Sieczkarek credits positive clinical data supporting the company's Essure System and improved patient reimbursement of the procedure with the company's 5,179 percent revenue growth from 2001-2005. Sieczkarek said, "As the technology leader in permanent birth control for women, we are well positioned to take advantage of the $3.6 billion sterilization market worldwide."

Conceptus' outstanding increase in revenues over the past five years resulted in a third-place ranking in the Scientific & Medical Equipment and Biotechnology category of the Technology Fast 50 for Silicon Valley. The average increase in revenues among companies who made the Technology Fast 50 for this region was 1,464 percent.

"To rank on Deloitte's Technology Fast 50, companies must have phenomenal revenue growth over five years," said Mark Jensen, National Director of the Venture Capital Services Group for Deloitte & Touche LLP in San Jose. "Conceptus has proven to be one of the fast-growth success stories in Silicon Valley, and we applaud their dedication to making their vision a reality."

To qualify for the Technology Fast 500, companies must have had operating revenues of at least $50,000 in 2001 and $5,000,000 in 2005, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.

Winners of the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte's Technology Fast 500 program, which ranks North America's top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Technology Fast 50 or Technology Fast 500 programs, visit www.fast500.com.

This year's Silicon Valley Technology Fast 50 program is co-presented by Deloitte & Touche USA LLP and Silicon Valley Bank, Cooly Godward Kronish LLP, Korn/Ferry International and Porsche Motorsports.

About the Essure Procedure

The Essure procedure deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the fallopian tube. An Essure procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. A woman is able to return home about 45 minutes after the procedure is completed. There is a three-month waiting period after the procedure during which women must use another form of birth control. The Essure procedure is 99.80% effective after four years of follow-up. The Essure procedure has been demonstrated in a small portion of the women undergoing clinical studies to be 99.74% effective based on 5 years of follow-up. Five year follow-up of all patients in clinical trials is ongoing.

About Conceptus

Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually.

Additional information about the Essure procedure is available at www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at www.conceptus.com or by calling 1-877-ESSURE2.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte", "Deloitte & Touche", "Deloitte Touche Tohmatsu" or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.

Deloitte & Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu. In the US, services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP.